Roth Capital affirms its Buy rating and $7 price target on BioLineRx Ltd. (Nasdaq: BLRX) after the company announced the presentation of successful final results of BL-8040's Phase 2a clinical trial in relapsed or refractory acute myeloid leukemia (r/r AML).
Analyst Joseph Pantginis commented today, The final r/r AML data continue to point to a bright path forward... More